The National Cancer Institute defines the 'lost generation' of cancer patients as adolescent and young adult patients 15 to 39 years of age. These patients have demonstrated lower rates of improvements in survival and the lowest rate of participation in federally-funded clinical trials. Host Dr. Jerome Lisk talks with Dr. David Freyer, director of the LIFE Survivorship and Transition Program at Children's Hospital Los Angeles, about the challenges facing this group of cancer patients.
advertisement
The Lost Generation of Cancer Patients
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The National Cancer Institute defines the 'lost generation' of cancer patients as adolescent and young adult patients 15 to 39 years of age. These patients have demonstrated lower rates of improvements in survival and the lowest rate of participation in federally-funded clinical trials. Host Dr. Jerome Lisk talks with Dr. David Freyer, director of the LIFE Survivorship and Transition Program at Children's Hospital Los Angeles, about the challenges facing this group of cancer patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
MinuteCE®
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
1.25 credits
<p>Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation</p>
MinuteCE®
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
0.75 credits
<p>A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?